ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.64
0.22%
US Tech 100
20,266.40
0.33%
S&P 500
5,969.34
0.35%
US Dollar vs CAD
1.39805
-0.03%
Bitcoin
98,569.35
-0.47%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Prime Medicine Inc (PRME) Share Price

Prime Medicine Inc

Prime Medicine Inc (PRME)

Prim SA
Prim SA
Prim SA
Prim SA
Prime Drink Group Corp
3.20
0.23
(7.74%)
Closed November 23 3:00PM
Delayed by 15 minutes
3.26
0.06
(1.88%)
After Hours: 5:53PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
3.26
Bid
3.05
Ask
3.35
Volume
1,486,969
2.96 Day's Range 3.29
2.85 52 Week Range 9.86
Market Cap
427.584M
Previous Close
2.97
Open
2.96
Last Trade
200
@
3.26
(formt)
Last Trade Time
Financial Volume
US$ 4,711,111
VWAP
3.1683
Average Volume (3m)
1,571,776
Shares Outstanding
131,160,842
Dividend Yield
-
PE Ratio
-2.12
Earnings Per Share (EPS)
-1.51
Revenue
-
Net Profit
-198.13M

About Prime Medicine Inc

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome a... Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.primemedicine.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Prime Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PRME. The last closing price for Prime Medicine was US$2.97. Over the last year, Prime Medicine shares have traded in a share price range of US$ 2.85 to US$ 9.86.

Prime Medicine currently has 131,160,842 shares outstanding. The market capitalization of Prime Medicine is US$389.55 million. Prime Medicine has a price to earnings ratio (PE ratio) of -2.12.

Ask ADVFN Intelligence (AI)

PRME Latest News

More News

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

13 hours ago
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 12 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 12 2024
Edgar (US Regulatory)

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

-- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024 and remains on...

November 12 2024
GlobeNewswire Inc.

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

November 06 2024
GlobeNewswire Inc.

Form 8-K - Current report

October 24 2024
Edgar (US Regulatory)

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies...

October 24 2024
GlobeNewswire Inc.

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

-- On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime...

October 15 2024
GlobeNewswire Inc.

Form 8-K - Current report

September 30 2024
Edgar (US Regulatory)

Prime Medicine Unveils Strategically Focused Pipeline

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently...

September 30 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.35-9.695290858733.613.612.8513016413.14937114CS
4-0.92-22.0095693784.184.712.8510474323.79840386CS
12-1.06-24.5370370374.325.022.8515717763.81268063CS
26-4.82-59.65346534658.088.14422.8511546214.54998655CS
52-3.67-52.95815295826.939.862.859209975.46512596CS
156-15.71-82.814971006918.9721.73012.856197817.67832095CS
260-15.71-82.814971006918.9721.73012.856197817.67832095CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

PRME Discussion

View Posts
Monksdream Monksdream 1 month ago
PRME under $5
👍️0
Monksdream Monksdream 2 months ago
PRME new 52 week low
👍️0
Invest-in-America Invest-in-America 2 months ago
PRME: Glad I grabbed a chunk of THIS ONE!!!!
👍️0
PonkenPlonken PonkenPlonken 2 months ago
"Under the terms of the agreement, Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5 billion in milestones,..."

"On the Effective Date, the Company entered into the Purchase Agreement with BMS, pursuant to which the Company agreed to issue and sell, and BMS agreed to purchase, in an unregistered offering (the “Offering”), 11,006,163 shares [...] for an aggregate purchase price of $55.0 million..."
👍️0
Monksdream Monksdream 3 months ago
PRME new 52=week low
👍️0
wiwineguy wiwineguy 3 months ago
K. I'm in!
👍️0
Monksdream Monksdream 3 months ago
DAKT
👍️0
wiwineguy wiwineguy 3 months ago
You are amazing Monk. Any recommendations
👍️0
Monksdream Monksdream 3 months ago
PRME under $5
👍️0
Monksdream Monksdream 3 months ago
PRME new 52 week low
👍️0
Monksdream Monksdream 4 months ago
PRME under $6
👍️0
Monksdream Monksdream 5 months ago
PRME under $10:
👍️0
Monksdream Monksdream 6 months ago
Great post
Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
I think she has been buying on the decline
She isn’t particularly interested in how well or how lousy the management controls costs it’s the potential she believes exists
There are about a dozen, if not more, listed gene editing companies
Not all will make it before they run out of money and have to raise more operating capital
Notice the $2 to $4 bounces on the way to lower lows
👍️0
Monksdream Monksdream 6 months ago
PRME under $10
👍️0
jondoeuk jondoeuk 6 months ago
PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0
👍️0
NY1972 NY1972 7 months ago
This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?
👍️0
jondoeuk jondoeuk 7 months ago
I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.
👍️0
jondoeuk jondoeuk 9 months ago
The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.
👍️0

Your Recent History

NASDAQ
PRME
Prime Medicine
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved